Hit parade for adoptive cell transfer therapy: The best T cells for superior clinical responses

Cancer Discovery

Volumn 3, Issue 4, 2013, Pages 379-381

  Speiser, Daniel E ^a,b  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

T LYMPHOCYTE RECEPTOR;

ADOPTIVE TRANSFER; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL (TOPIC); GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOTHERAPY; MAJOR HISTOCOMPATIBILITY COMPLEX; METASTATIC MELANOMA; NONHUMAN; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE;

FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MALE; MART-1 ANTIGEN; MELANOMA; SKIN NEOPLASMS; T-LYMPHOCYTES;

EID: 84877666366     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-13-0064     Document Type: Article

References (15)

1. Ho WY, Blattman JN, Dossett ML, Yee C, Greenberg PD. Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction. Cancer Cell 2003; 3: 431-7.
2. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011; 17: 4550-7.
3. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol Nature Publishing Group 2012; 12: 269-81.
4. Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009; 114: 535-46.
5. Ma C, Cheung AF, Chodon T, Koya RC, Wu Z, Ng C, et al. Multifunctional T-cell analyses to study response and progression in adoptive cell transfer immunotherapy. Cancer Discov 2013;3:418-29.
6. Zhou Q, Schneider IC, Edes I, Honegger A, Bach P, Schonfeld K, et al. T-cell receptor gene transfer exclusively to human CD8eecells enhances tumor cell killing. Blood 2012; 120: 4334-42.
7. Nishimura T, Kaneko S, Kawana-Tachikawa A, Tajima Y, Goto H, Zhu D, et al. Generation of rejuvenated antigen-specific T cells by reprogramming to pluripotency and redifferentiation. Stem Cell 2013; 12: 114-26.
8. Lugli E, Dominguez MH, Gattinoni L, Chattopadhyay PK, Bolton DL, Song K, et al. Superior T memory stem cell persistence supports longlived T cell memory. J Clin Invest 2013 Jan 2. [Epub ahead of print].
9. Speiser DE, Kyburz D, Stübi U, Hengartner H, Zinkernagel RM. Discrepancy between in vitro measurable and in vivo virus neutralizing cytotoxic T cell reactivities. Low T cell receptor specificity and avidity sufficient for in vitro proliferation or cytotoxicity to peptide-coated target cells but not for in vivo protection. J Immunol 1992; 149: 972-80.
10. Alexander-Miller MA, Leggatt GR, Berzofsky JA. Selective expansion of high-or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc Natl Acad Sci U S A 1996; 93: 4102-7.
11. Baitsch L, Fuertes Marraco SA, Legat A, Meyer C, Speiser DE. The three main stumbling blocks for anticancer T cells. Trends Immunol 2012; 33: 364-72.
12. Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF, Zheng Z, et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother 2013; 36: 133-51.
13. Hebeisen M, Rufer N, Oberle S, Speiser DE, Zehn D. Signaling mechanisms that balance antiviral, auto-reactive, and anti-tumor potential of low affinity T cells. J Clin Cell Immunol 2012; S12: 003.
14. Speiser DE, Baumgaertner P, Voelter V, Devêvre E, Barbey C, Rufer N, et al. Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen. Proc Natl Acad Sci U S A 2008; 105: 3849-54.
15. Rizzuto GA, Merghoub T, Hirschhorn-Cymerman D, Liu C, Lesokhin AM, Sahawneh D, et al. Self-antigen-specific CD8AAT cell precursor frequency determines the quality of the antitumor immune response. J Exp Med 2009; 206: 849-66.